339 related articles for article (PubMed ID: 25123150)
1. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
[TBL] [Abstract][Full Text] [Related]
2. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
[TBL] [Abstract][Full Text] [Related]
3. Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
Sieuwerts AM; Schrijver WA; Dalm SU; de Weerd V; Moelans CB; Ter Hoeve N; van Diest PJ; Martens JW; van Deurzen CH
PLoS One; 2017; 12(1):e0171343. PubMed ID: 28141868
[TBL] [Abstract][Full Text] [Related]
4. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
6. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
[TBL] [Abstract][Full Text] [Related]
7. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
[TBL] [Abstract][Full Text] [Related]
8. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
9. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
Schmidt M; Petry IB; Böhm D; Lebrecht A; von Törne C; Gebhard S; Gerhold-Ay A; Cotarelo C; Battista M; Schormann W; Freis E; Selinski S; Ickstadt K; Rahnenführer J; Sebastian M; Schuler M; Koelbl H; Gehrmann M; Hengstler JG
Breast Cancer Res Treat; 2011 Feb; 125(3):637-46. PubMed ID: 20352488
[TBL] [Abstract][Full Text] [Related]
10. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
[TBL] [Abstract][Full Text] [Related]
12. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
13. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
14. Unfavorable prognosis and clinical consequences of APOBEC3B expression in breast and other cancers: A systematic review and meta-analysis.
Jafarpour S; Yazdi M; Nedaeinia R; Ghobakhloo S; Salehi R
Tumour Biol; 2022; 44(1):153-169. PubMed ID: 36093650
[TBL] [Abstract][Full Text] [Related]
15. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.
Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M
PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.
Periyasamy M; Patel H; Lai CF; Nguyen VTM; Nevedomskaya E; Harrod A; Russell R; Remenyi J; Ochocka AM; Thomas RS; Fuller-Pace F; Győrffy B; Caldas C; Navaratnam N; Carroll JS; Zwart W; Coombes RC; Magnani L; Buluwela L; Ali S
Cell Rep; 2015 Oct; 13(1):108-121. PubMed ID: 26411678
[TBL] [Abstract][Full Text] [Related]
17. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3B is an enzymatic source of mutation in breast cancer.
Burns MB; Lackey L; Carpenter MA; Rathore A; Land AM; Leonard B; Refsland EW; Kotandeniya D; Tretyakova N; Nikas JB; Yee D; Temiz NA; Donohue DE; McDougle RM; Brown WL; Law EK; Harris RS
Nature; 2013 Feb; 494(7437):366-70. PubMed ID: 23389445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
